Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 316 Shares

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 316 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $44.90, for a total transaction of $14,188.40. Following the completion of the transaction, the insider now owns 113,171 shares in the company, valued at $5,081,377.90. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The shares were sold at an average price of $46.81, for a total transaction of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total transaction of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00.
• On Monday, November 4th, Dennis Cho sold 659 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $27,388.04.
• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $134,123.84.

Twist Bioscience Trading Up 0.7 %

Shares of Twist Bioscience stock traded up $0.33 on Thursday, reaching $49.23. 486,846 shares of the stock were exchanged, compared to its average volume of 939,671. The firm has a market capitalization of $2.92 billion, a PE ratio of -13.68 and a beta of 1.82. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The business has a fifty day moving average price of $45.51 and a two-hundred day moving average price of $46.72.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the third quarter worth $34,000. Signaturefd LLC boosted its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience during the 2nd quarter worth $61,000. Beaird Harris Wealth Management LLC purchased a new position in shares of Twist Bioscience in the 3rd quarter valued at about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after purchasing an additional 381 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Robert W. Baird boosted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. TD Cowen reissued a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research started coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Scotiabank raised their price target on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience has an average rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.